Gerberanın (Gerbera jamesonii Bolus) Yaprak ve Yaprak Sapından in vitro Adventif Sürgün rejenerasyonu

Çalışmada Rosalin gerbera çeşidinin yaprak ve yaprak sapı eksplanlarından sürgün rejenerasyonu üzerine bazı büyümeyi düzenleyici madde kombinasyonlarının etkileri araştırılmıştır. Bu amaçla MS ortamına benzil aminopürinin (BAP) 3 dozu (1.0, 2.0, ve 3.0mg/L) yada thidiazuronun (TDZ) 3 dozunun (0.3, 0.6, 1.2mg/L) gümüş nitratın 3 dozu (0, 1.0 ve 2.0 mg/L) ile oluşturduğu 18 farklı büyümeyi düzenleyici madde kombinasyonuilave edilmiştir.Ayrıca tüm uygulamalarda, MS ortamına 0.1 mg/l NAA eklenmiştir. Çalışmada her iki eksplant tipinde de kallus oluşumu bakımından TDZ uygulamaları BAP uygulamalarına göre daha iyi sonuç vermiştir.Eksplant olarak yapraklar kullanıldığında, hiçbir uygulamada sürgün oluşumu gözlenmemiştir.Çalışmada yaprak sapları eksplant olarak kullanıldığında ise, en yüksek sürgün rejenerasyon oranı, sürgün sayısı ve yaprak sayısı değerleri 3 mg/l BAP+0.1 mg/l NAA ilave edilmiş MS ortamında sırasıyla %22.5, 2.0 adet ve 3.33 adet olarak elde edilmiştir. Gümüş nitrat uygulamaları sürgün oluşumu üzerine etkili olmamıştır

A Multicenter Study of Genotype Variation/Demographic Patterns in 2475 Individuals Including 1444 Cases With Breast Cancer in Turkey

Objective: Breast cancer (BC) is the most common cancer type in women and may be inherited, mostly in an autosomal dominant pattern. The clinical diagnosis of BC relies on the published diagnostic criteria, and analysis of two genes, BRCA1 and BRCA2, which are strongly associated with BC, are included in these criteria. The aim of this study was to compare BC index cases with non-BC individuals in terms of genotype and diagnostic features to investigate the genotype/demographic information association. Materials and Methods: Mutational analyses for the BRCA1/BRCA2 genes was performed in 2475 individuals between 2013-2022 from collaborative centers across Turkey, of whom 1444 with BC were designated as index cases. Results: Overall, mutations were identified in 17% (421/2475), while the percentage of mutation carriers in cases of BC was similar, 16.6% (239/1444). BRCA1/BRCA2 gene mutations were detected in 17.8% (131/737) of familial cases and 12% (78/549) of sporadic cases. Mutations in BRCA1 were found in 4.9%, whereas 12% were in BRCA2 (p<0.05). Meta-analyses were performed to compare these results with other studies of Mediterranean-region populations. Conclusion: Patients with BRCA2 mutations were significantly more common than those with BRCA1 mutations. In sporadic cases, there was a lower proportion with BRCA1/BRCA2 variants, as expected, and these results were consistent with the data of Mediterranean-region populations. However, the present study, because of the large sample size, revealed more robust findings than previous studies. These findings may be helpful in facilitating the clinical management of BC for both familial and non-familial cases